β-内酰胺酶抑制剂复合制剂4917例不良反应报告分析

发布时间：2019-06-15 01:45

【摘要】：目的分析重庆市β-内酰胺酶抑制剂复合制剂所致药物不良反应(ADR)的特点和一般规律,为临床合理用药提供参考。方法对2008—2013年重庆市ADR监测中心接收的β-内酰胺酶抑制剂复合制剂致4 917例ADR报告进行回顾性统计分析。结果 4 917例报告中,老年患者与儿童患者比例较高;静脉滴注给药引发的ADR最多,占92.15%;含舒巴坦复合制剂引起的ADR居首位,占74.27%;所涉及药品前3位分别为头孢哌酮/舒巴坦2 077例(42.24%)、阿莫西林/舒巴坦698例(14.20%)及阿莫西林/克拉维酸钾652例(13.26%);ADR累及器官及系统以皮肤及其附件损害、全身性损害和消化系统损害最为常见。结论临床应重视β-内酰胺酶抑制剂复合制剂的ADR监测工作,减少或避免ADR的发生,保障临床用药安全有效。
[Abstract]:Objective to analyze the characteristics and general rules of adverse drug reactions (ADR) caused by 尾-lactamase inhibitor compound preparation in Chongqing, and to provide reference for rational use of drugs in clinic. Methods A retrospective analysis of 4917 cases of ADR caused by 尾-lactamase inhibitor compound preparation received by Chongqing ADR Monitoring Center from 2008 to 2013 was carried out. Results among the 4 917 cases, the proportion of elderly patients was higher than that of children, ADR caused by intravenous drip was the most, accounting for 92.15%, ADR caused by sulbactam compound preparation was the first, accounting for 74.27%, the first three drugs involved were cefoperazone / sulbactam in 2077 cases (42.24%), amoxicillin / sulbactam in 698 cases (14.20%) and amoxicillin / clavulanate in 652 cases (13.26%), and the first three drugs involved were cefoperazone / sulbactam in 2077 cases (42.24%), amoxicillin / sulbactam in 698 cases (14.20%) and amoxicillin / clavulanate potassium in 652 cases (13.26%). ADR involves organs and systems in which skin and its appendages are damaged, systemic damage and digestive system damage are the most common. Conclusion attention should be paid to the ADR monitoring of 尾-lactamase inhibitor compound preparation in order to reduce or avoid the occurrence of ADR and ensure the safety and effectiveness of clinical drug use.
【作者单位】：重庆市第九人民医院临床药学研究室;
【基金】：重庆市北碚区科委计划项目(2012-26)
【分类号】：R969.3

【参考文献】